SAFINAMIDE (safinamide) by Rk Pharma is unknown.
Drug data last refreshed 13h ago
unknown. XADAGO is an inhibitor of monoamine oxidase B (MAO-B). Inhibition of MAO-B activity, by blocking the catabolism of dopamine, is thought to result in an increase in dopamine levels and a subsequent increase in dopaminergic activity in the brain.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Safinamide vs Placebo for Pain in Patients With Parkinson's Disease and Motor Fluctuations
A Study to Evaluate the Efficacy and Safety of Safinamide Mesilate as Add-on Therapy to Levodopa in Parkinson's Disease Participants With Motor Fluctuation in South Korea
A Single and Multiple Dose Study to Assess How the Drug Enters, Moves Through and Exits the Body, Safety and Tolerability of Safinamide in Healthy Adult Chinese Volunteers
An Observational Study on Safinamide, Rasagiline and Other Standard of Care in PD
Safinamide for Multiple System Atrophy (MSA)
Worked on SAFINAMIDE at Rk Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.